V-DIG Audit: Teva Pharmaceuticals

Enterprise Technology Stack & Vendor Relationships

Teva Pharmaceuticals operates as a global pharmaceutical company headquartered in Kiryat Atidim technology park in Tel Aviv, Israel, with major operational sites throughout the country including Jerusalem, Kfar Saba, Netanya, and Ramat Hovav ¹. The company publicly selected Amazon Web Services (AWS) as its preferred cloud provider in December 2019, committing to a multi-year global engagement covering migration of SAP workloads and core enterprise applications ². This relationship has remained active according to subsequent corporate disclosures, positioning AWS as Teva’s primary cloud infrastructure partner.

Teva operates SAP as its global ERP backbone, a configuration referenced across investor filings and ESG disclosures ². The company invested over $10 million in cloud HR technology, implementing SAP SuccessFactors to replace 30 local HR solutions across 80 countries ³. AKT (formerly) served as the systems integrator for this SAP SuccessFactors implementation ⁴.

A systematic review of Teva’s Form 20-F filings, ESG Progress Reports, corporate press releases, and NGO company databases found no confirmed licensing, subscription, or integration relationship with any Israeli-founded or Israeli-headquartered technology vendors including Check Point Software, CyberArk, Wiz, SentinelOne, Claroty, NICE Systems, Verint Systems, or Palo Alto Networks. No public evidence identified.

Teva does not publicly name the systems integrators engaged for its AWS migration or SAP programme beyond AKT for SAP SuccessFactors. Whether any integrator mandated, recommended, or deployed Israeli-origin technology components as part of these engagements is not disclosed. No public evidence identified.

Surveillance, Biometrics & Retail Technology

Teva is a pharmaceutical manufacturer and distributor; it does not operate conventional retail storefronts and its commercial model does not involve customer-facing physical premises where retail-surveillance or frictionless-checkout technology would be deployed ¹.

Platform checks for Trigo, BriefCam, AnyVision/Oosto, and Trax (all Israeli-origin) returned no results across 20-F filings, ESG reports, and NGO company profiles. No public evidence identified.

No evidence of deployment of Israeli-origin predictive-policing, sentiment-analysis, social-media monitoring, or workforce-surveillance tools appears in any source class reviewed. No public evidence identified.

No evidence that such technologies reach Teva indirectly via managed-security-service providers, third-party analytics platforms, or bundled software suites. No public evidence identified.

Cloud Infrastructure, Data Residency & Sovereign Cloud Participation

Teva is incorporated and headquartered in Israel, with its global headquarters in Kiryat Atidim technology park in Tel Aviv ¹. Substantial operational sites are maintained at Jerusalem, Kfar Saba, Netanya, and Ramat Hovav. Local IT infrastructure exists for internal operational use at these sites, though specific vendors or configurations are not publicly disclosed.

Teva had planned a new headquarters campus in Ra’anana city to house 3,000 employees, being built by Tidhar and Electra companies ⁵. However, Teva has suspended its Ra’anana headquarters plans due to heavy debts ⁶.

Teva is a consumer of cloud infrastructure, not a provider. Its primary platform is AWS ². Teva does not market, sell, or operate cloud, data-residency, or sovereign-cloud services to external customers.

Project Nimbus, the Israeli government’s national cloud contract, was awarded jointly to Google Cloud and Amazon Web Services in April 2021 ⁷. Teva is not a Project Nimbus vendor and has no disclosed role as a supply-chain participant in that programme. However, as an AWS customer with Israeli operations, Teva may consume capacity from the AWS Israel region that physically overlaps Nimbus infrastructure; this is not publicly disclosed and cannot be confirmed or excluded from available sources.

The provision of data-sovereignty or resilience infrastructure to Israeli state institutions is outside Teva’s product scope. No public evidence identified.

Defence, Intelligence & Security Sector Technology Relationships

NGO databases indicate that Teva supplies pharmaceuticals — primarily generic medicines — to Israeli health funds and to the IDF medical corps ⁸⁹. These are pharmaceutical supply relationships, not technology contracts. The distinction is material: Teva’s defence-sector exposure is as a medicines supplier, not as a provider of IT, communications, hosting, or analytics services.

Teva was recognized by the IDF in 2009 as having an “exemplary” relationship with reservist employees ⁹. In Q3 2023, nearly 10% of Teva’s Israeli staff were called into military reserve duty ¹⁰.

No evidence of technology contracts — IT services, hosting, communications, analytics, or cybersecurity — between Teva and the Israeli Ministry of Defence, IDF units, or domestic or foreign intelligence agencies appears in 20-F filings, ESG disclosures, or NGO databases. No public evidence identified.

Teva does not produce dual-use ICT or surveillance technology; its manufactured products are pharmaceutical. No public evidence identified.

Offensive cyber tooling, zero-day vulnerability exploitation, and digital-weapons systems are entirely outside Teva’s business domain. No public evidence identified.

AI, Algorithmic & Autonomous Systems

Teva occupies the role of an AI/ML customer, not a developer or provider. Cloud-based AI and machine-learning services consumed via AWS ² and, historically, IBM Watson are applied internally to drug-discovery pipelines, manufacturing-process analytics, pharmacovigilance signal detection, and patient-support platforms. Teva’s 2024 ESG Progress Report references digital and data capabilities but does not describe proprietary AI systems offered to external parties ¹¹.

Teva is a founding partner of AION Labs, an AI-driven drug discovery venture studio founded in 2021 in Israel, alongside AstraZeneca, Merck KGaA, Pfizer, and AWS ¹². This is an AI drug discovery initiative, not an AI/ML system provided to state bodies.

No evidence of Teva providing any AI or algorithmic system to Israeli state agencies, military units, or security services appears in any reviewed source. No public evidence identified.

No evidence that Teva’s AI/ML systems are trained on civilian-population datasets, intercepted communications, or surveillance datasets sourced from Israel or the occupied Palestinian territories. No public evidence identified.

Autonomous targeting, automated kinetic threat-detection, and autonomous-tracking systems are outside Teva’s product domain. No public evidence identified.

Technology Ecosystem & R&D Footprint

Teva operates substantial pharmaceutical R&D infrastructure in Israel, including a global innovation centre at Netanya, specialty-pharma research at Jerusalem, and additional facilities at Kfar Saba ¹. The R&D focus is pharmaceutical — synthetic chemistry, drug formulation, biologics, and respiratory-device development — not ICT, cybersecurity, or AI products. These operations are ongoing.

Teva has active R&D partnerships with Technion for cancer and neurobiology research ¹³, the Weizmann Institute for antibody research ¹⁴, and Tel Aviv University for early-stage drug research ¹⁵. These partnerships are pharmaceutical in nature. Current ICT-domain co-development agreements with the Technion, Hebrew University, or Weizmann Institute are not identified in public disclosures. No public evidence identified.

Teva launched the Rise open innovation platform in January 2024, partnering with Israeli startups for AI, digital health, and Industry 4.0 ¹⁶. The program has a budget of $10 million in partnership with the Israel Innovation Authority and Startup Nation Central ¹⁷. This focuses on pharmaceutical innovation, not surveillance or cybersecurity technology.

Teva’s major acquisitions — Cephalon (2011), Allergan Generics/Actavis (2016), and Anda (2016) — are pharmaceutical transactions ¹. No Israeli ICT, cybersecurity, AI, biometrics, or dual-use technology company has been identified as a Teva acquisition target in public filings or press releases. No public evidence identified.

Teva has participated in Israeli digital-health innovation programmes referenced in Israel Innovation Authority annual reporting. Specific limited-partner positions in Israeli venture-capital funds or named minority investments in Israeli ICT startups are not enumerated in public filings. No public evidence identified.

Civil Society Scrutiny & Regulatory History

Multiple sources confirm Teva is listed in the UN OHCHR database of businesses involved in Israeli settlement activity ¹⁸. Who Profits explicitly documents that “Teva enjoys the advantages generated by the Israeli occupation of Palestinian lands allowing the company to exploit the Palestinian market” through the captive market mechanism ⁸.

The Who Profits Research Center maintains an active profile on Teva documenting its Israeli incorporation, pharmaceutical supply to Israeli state institutions (including health funds and the IDF medical corps), and corporate operations within Israel ⁸. The profile does not characterise Teva as a technology vendor to the Israeli state or military.

Teva’s Israeli subsidiary Salomon, Levin & Elstein operates as Teva’s distribution unit throughout Israel and the Occupied Palestinian Territory ¹⁹. This is pharmaceutical distribution, not technology provision.

The BDS National Committee has issued a public statement explicitly stating that it does not target Teva, citing Palestinian patient and community dependence on affordable Teva generic medicines ²⁰. Grassroots calls for pharmaceutical-sector divestment from Teva exist in some activist communities but have not been formally adopted at the BDS NC level.

No regulatory enforcement actions, export-control violations, or legal proceedings concerning Teva’s technology exports or supply of technology services to Israeli state entities have been identified. No public evidence identified.

CEO Richard Francis publicly expressed support for IDF following October 7 attacks, stating “Is there any other company in a country that could have been part of a war and still performed the way it did?” ²¹⁹.

No evidence Teva has issued public statements or changed operations following ICJ advisory opinion (July 2024) or ICC arrest warrants (November 2024). Teva’s ESG reports (Healthy Future) contain no reference to these legal proceedings. No public evidence identified.

End Notes